Journals / Glokom Katarakt / 2006 / Cilt: 1 - Sayı: 1

Enhancement of the success rate in trabeculectomy: Large area mitomycin-C application

Trabekülektomide başarının arttırılması: Geniş alan mitomisin C uygulaması

Pages
7–12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Large area MMC application seems to increase long term success rates without increasing the complication rates in trabeculectomy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare the effects of variable Mitomycin-C (MMC) application areas during trabeculectomy on target intraocular pressure (IOP), antiglaucomatous therapy, surgical complications and bleb morphology.
📊
Key Findings & Data:Materials and Methods: Sixty six cases with primary open angle (PAAG) glaucoma who underwent trabeculectomy combined with small area (Group 1) and large area (Group 2) MMC application were evaluated retrospectively.
💡
Conclusion & Impact:Conclusion: Large area MMC application seems to increase long term success rates without increasing the complication rates in trabeculectomy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Mitomisin · Glokom · açık-açılı

Abstract

Purpose: To compare the effects of variable Mitomycin-C (MMC) application areas during trabeculectomy on target intraocular pressure (IOP), antiglaucomatous therapy, surgical complications and bleb morphology. Materials and Methods: Sixty six cases with primary open angle (PAAG) glaucoma who underwent trabeculectomy combined with small area (Group 1) and large area (Group 2) MMC application were evaluated retrospectively. MMC had only been applied to the scleral flap area in Group 1. whereas upper temporal and nasal quadrant in addition to the flap area in Group 2. The cases with narrow angle glaucoma, secondary glaucoma, history of previous ocular surgery and follow up period less than 2 years were exluded from the study. A full ophthalmological examination was performed in all cases and IOP measurements, morphology and the function of the blebs, necessity for anti-glaucomatous medications and complications at 1st month and 2nd year were evaluated. Results: There were 32 cases (48.5%) in Group 1 and 34 cases (51.5%) in Group 2. The mean IOPs were 12.6±5.5 and 10.8±5.3 mmHg at 1st month (p>0.05), whereas 14.4±2.8 and 10.1±2.6 mmHg at 2nd year, respectively (p<0.05). The mean number of medications were 3.3±1.6 and 3.2±0.2 at 1st month (p>0.05), whereas 0.8±1.2 and 0.26±0.70 at 2nd year (p<0.05). There were more thin, diffuse and functional blebs in Group 2 than those of Group 1 (p>0.05), and cystic blebs were seen less than those of Group 1 (p>0.05). Conclusion: Large area MMC application seems to increase long term success rates without increasing the complication rates in trabeculectomy.

Özet

Amaç: Trabekülektomi ile birlikte kullanılan Mitomisin-C’nin (MMC) uygulama alanındaki farklılıkların hedef göz içi basıncı (GİB), antiglokomatöz tedavi, cerrahi komplikasyonlar ve bleb morfolojisine olan etkilerinin karşılaştırılması amaçlanmaktadır. Gereç ve Yöntem: Tek alan (Grup 1) ve geniş alan (Grup 2) MMC ile birlikte trabekülektomi uygulanan, primer açık açılı glokomlu toplam 66 olgu retrospektif olarak incelendi. MMC Grup 1’ de sadece skleral flep alanına uygulanırken; Grup 2’de skleral flep alanına ek olarak, nazal ve temporal subkonjonktival alanlara aynı süre ve dozda (0.2 mg/ml 2 dakika) uygulandı. Dar açılı, sekonder glokomlu, cerrahi geçirmiş, 2 yıldan az takibi olan olgular çalışma dışı bırakıldı. Olguların tümünde tam oftalmolojik muayene yapılarak; 1. ay ve 2. yılda GİB, blep fonksiyon ve morfolojisi, ek antiglokomatöz tedavi gereksinimi ve komplikasyonlar değerlendirildi. Bulgular: Olguların 32’sinde (%48.5) tek alan MMC uygulanırken; 34’ünde (%51.5) geniş alan MMC uygulaması yapıldı. Ortalama GİB postoperatif 1. ayda Grup 1 ve 2’de sırasıyla 12.6±5.5 mmHg ve 10.8±5.3 mmHg olarak saptanırken (p>0.05); 2. yılda sırasıyla 14.4±2.8 mmHg ve 10.1±2.6 mmHg olarak bulundu (p 0.05); postoperatif 2. yılda sırasıyla 0.8±1.2 ve 0.26±0.7 olarak saptandı (p 0.05), kistik bleb daha az izlendi (p>0.05). Sonuç: MMC’nin antifibrotik etkisinin konjonktiva altına yayılması (geniş alan MMC uygulaması) trabekülektomide geç dönem başarıyı komplikasyon oranını değiştirmeden arttırabilmektedir.

🔖

Cite This Article

ÖNOL, M., PEHLİVANLI, Z., HASANREİSOĞLU, B. (2006). Enhancement of the success rate in trabeculectomy: Large area mitomycin-C application. Glokom Katarakt, Cilt: 1 - Sayı: 1, 7–12. https://ajindex.com/articles/226723

References (1)

  1. Cairns DE.: Trabeculectomy - a preliminary report of a new method. Am J Ophthalmol 1968;66:673-679. 2. Lama PJ, Fechtner RD: Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48:314-346. 3. Chen CW: Enhanced intraocular pressure controlling effectiveness of trabeculectomy by local application of mitomycin C. Trans Asia Pac Acad Ophthalmol 1983;9:172-177. 4. Membrey WL, Bunce C, Poinoosawmy DP et al.: Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma. 2. Visual field progression. Br J Ophthalmol 2001;85: 96-701. 5. Singh K, Mehta K, Shaikh NM et al.: Trabeculectomy with intraoperative mitomyin C versus 5-fluorouracil. Prospective randomised clinical trial. Ophthalmology 2000;107:2305-2309. 6. Maquet JA, Dios E, Aragon J et al.: Protocol for mitomycin C use in glaucoma surgery. Acta Ophthalmol Scand 2005;83;l96-200. 7. Cordeiro FM, Constable PH, Alexander RA et al.: Effect of varying treatment area in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 1997;38:1639-1646. 8. Lama PJ, Fechtner RD: Antifibrotics and wound healing in glaucoma surgery. Survey Ophthalmol 2003;48:314-346. 9. Salmon SE, Sartorelli AC: Cancer chemotherapy, in Katsung BG (ed): Basic and Clinical Pharmacology. Norwalk, CT, Appleton and Lange, 1987;680-681. 10. Zacharia PT, Deppermann SR, Schuman JS: Ocular hypotony after trabeculectomy with mitomycin C. Am J Ophthalmol 1993,116:314-326. 11. Jampel HD, Quigley HA, Kerrigan-Baumrind LA et al.: Risk factors for late-onset infection following glaucoma filtration surgery. Arch Ophthalmol 2001;119:1001-1008. 12. Wells AP, Codeiro MF, Bunce C et al.: Cystic bleb formation and related complications in limbus - versus fornix - based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin-C. Ophthalmology 2003;ll 0:2192-2197. 13. Khaw PT: Advances of glaucoma surgery: evolution of anti metabolite adjunctive therapy. J Glaucoma 2001;10:81 -84. 14. Akarsu C, Onol M, Hasanreisoğlu B.: Postoperative 5-FU versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow-up. Clin Exp Ophthalmol 2003;31:199-205. 15. Jampel HD: Effect of brief exposure to mitomyin C on viability and proliferation of cultured human Tenon's capsule fibroblast. Ophthalmology 1992; 99:1471-1476. 16. Cohen JS, Novack GD, Li ZL: The role of mitomycin C treatment duration and previous intraocular surgery on the success of trabeculectomy surgery. J